PEPCK1 Antisense Oligonucleotide Prevents Adiposity and Impairs Hepatic Glycogen Synthesis in High-Fat Male Fed Rats.

Autor: Beddow SA; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; West Haven Veterans Affairs Medical Center, West Haven, Connecticut., Gattu AK; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; West Haven Veterans Affairs Medical Center, West Haven, Connecticut., Vatner DF; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Paolella L; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; West Haven Veterans Affairs Medical Center, West Haven, Connecticut., Alqarzaee A; West Haven Veterans Affairs Medical Center, West Haven, Connecticut., Tashkandi N; West Haven Veterans Affairs Medical Center, West Haven, Connecticut., Popov VB; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Church CD; Department of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut., Rodeheffer MS; Department of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut., Cline GW; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut., Geisler JG; Mitochon Pharmaceutical, Blue Bell, Pennsylvania., Bhanot S; Ionis Pharmaceuticals, Carlsbad, California., Samuel VT; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.; West Haven Veterans Affairs Medical Center, West Haven, Connecticut.

Publikováno v: Endocrinology [Endocrinology] 2019 Jan 01; Vol. 160 (1), pp. 205-219.

Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance.

Autor: Kumashiro N; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA., Beddow SA, Vatner DF, Majumdar SK, Cantley JL, Guebre-Egziabher F, Fat I, Guigni B, Jurczak MJ, Birkenfeld AL, Kahn M, Perler BK, Puchowicz MA, Manchem VP, Bhanot S, Still CD, Gerhard GS, Petersen KF, Cline GW, Shulman GI, Samuel VT

Publikováno v: Diabetes [Diabetes] 2013 Jul; Vol. 62 (7), pp. 2183-94. Date of Electronic Publication: 2013 Feb 19.

Fasting hyperglycemia in the Goto-Kakizaki rat is dependent on corticosterone: a confounding variable in rodent models of type 2 diabetes.

Autor: Beddow SA; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA., Samuel VT

Publikováno v: Disease models & mechanisms [Dis Model Mech] 2012 Sep; Vol. 5 (5), pp. 681-5. Date of Electronic Publication: 2012 Aug 03.

FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

Autor: Kir S; Department of Pharmacology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390, USA., Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ

Publikováno v: Science (New York, N.Y.) [Science] 2011 Mar 25; Vol. 331 (6024), pp. 1621-4.

Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

Autor: Samuel VT; Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06536, USA., Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2007 Mar; Vol. 117 (3), pp. 739-45. Date of Electronic Publication: 2007 Feb 22.